Measuring sCD160 in Blood and Eye Fluid in Diabetic Retinopathy and Retinal Vein Occlusion
Measures sCD160 in blood and eye fluid of adults with retinal disease.
Key facts
- Who runs it
- CHU de Reims
- Where
- Reims, FranceSee the site
- Trial code
- Registry title
- Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 27 Jun 2018
- Expected to end
- 27 Feb 2028
- Type of study
- Interventional
- Treatments tested
- sampling of ophthalmic liquid
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with or without ischaemic retinopathy, such as diabetic retinopathy or retinal vein occlusion. Eye fluid and blood samples are taken to measure the sCD160 protein.
- Age
- Over 18 years old.
- Sex
- All sexes can join.
- Disease stage
- The record does not give a stage. It names diabetic retinopathy and retinal vein occlusion; people with and without ischaemic retinopathy are compared.
- Earlier treatment
- No anti-VEGF therapy, corticosteroids or immunosuppressive agents in the last 3 months or at the same time. No previous systemic anti-VEGF treatment.
- Biomarker or test result
- Serum C-reactive protein (CRP) must not be above 10mg/mL.
Main reasons for not taking part
- Previous eye surgery on the retina or vitreous, eye tumour, severe eye injury or eye radiation
- Severe eye infection or inflammation, or active inflammation or infection outside the eye in the last 4 weeks before surgery
- History of inflammatory or autoimmune disease
- Serious allergy to fluorescein sodium used in angiography
- C-reactive protein above 10mg/mL
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- over 18 years old
- with social security affiliation
- willing to participate this study non-inclusion criteria :
- any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents
- any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation
- any serious allergy to the fluorescein sodium for injection in angiography
- any history of previous systemic anti-VEGF treatment
- any history of inflammatory or auto-immune disease
- any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria :
- Patients with C-reactive protein CRP > 10mg/mL (serum sampling during surgery)
Where in France
- CHU ReimsReims, FranceContact: Damien JOLLYTaking people
About the trial
What the trial wants to find out
CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.
Read full original descriptionShow less
The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.
The group in the trial
- Patients with ophthalmic surgeryTreatment being tested
Treatment: sampling of ophthalmic liquid
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
- Plain-language title
- Measuring sCD160 in Blood and Eye Fluid in Diabetic Retinopathy and Retinal Vein OcclusionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 April 2026